TTBK2

Across TCGA pan-cancer cohorts, TTBK2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated TTBK2 data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher TTBK2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TTBK2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, UCEC, and BRCA are the cancer types where TTBK2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.338	0.692	.023	24	view →
UCEC	DFS	Median	All	0.917	0.615	.013	24	view →
BRCA	DFS	Median	III,IV	0.093	0.880	<.001	23	view →
LUAD	DFS	Median	All	0.453	0.794	.030	8	view →
SARC	DFS	Median	All	0.200	0.616	.003	6	view →
SKCM	DFS	Median	II,III,IV	0.287	0.718	.001	6	view →
PRAD	DFS	Median	All	0.177	0.777	.006	4	view →
HNSC	OS	Median	II,III,IV	0.344	0.653	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

TTBK2–OV (OS)

Open the OV breakdown →